Mind Medicine MindMed

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mind Medicine (MNMD) reports robust financials and advances in psychedelic research

Mind Medicine (MNMD) showcased strong financials, R&D progress, and strategic advancements in its Q4 2022 earnings call.
The company's focus on safety, responsible distribution, and talent acquisition positions it well for future growth and innovation.
Challenges in patient enrollment, dosing strategies, and commercialization strategies require strategic planning and clear execution for success.

Mind Medicine (MNMD) reports positive trial data and strong financials

Mind Medicine (MNMD) showcases progress in pipeline development with positive trial results and a strong financial position. The company's focus on advancing treatments for brain health disorders and efficient cash management highlights its commitment to growth and innovation.

MindMed (MNMD) reports Q2 loss, progresses on innovative treatments

MindMed (MNMD) is advancing its R&D pipeline with a focus on MM-120 for GAD and MM-402 for Autism spectrum disorder. Financially, the company maintains a strong position with cash reserves for ongoing operations. Emphasis on placebo-controlled research and innovative formulation technologies highlights a commitment to scientific rigor and product development.

Mind Medicine (MNMD) reports strong financials and promising R&D progress

Mind Medicine (MNMD) is making significant strides in developing innovative treatments for mental health disorders, with promising lead candidates MM-120 and MM-402. While facing increased R&D expenses and analyst scrutiny, the company's strong financial position and focus on unmet needs present opportunities for future growth.

MindMed reports positive Phase IIb results for MM120 in GAD

MindMed's financial performance in 2023 reflected a net loss of $95.7 million but maintained a strong cash position of $99.7 million.
The Phase IIb trial results for MM120 in GAD were positive, demonstrating significant reductions in HAM-A scores and high clinical response rates.
While facing challenges in trial design and demonstrating drug effects, MindMed remains focused on innovation and addressing unmet medical needs.
Opportunities lie in expanding product indications, developing new therapies, and engaging with regulatory authorities to advance their pipeline.

MindMed reports strong Q1 earnings, advances transformative treatments

MindMed's financials remain strong with significant cash reserves and positive trial outcomes for MM-120.
Strategic focus on advancing MM-120 and MM-402 programs while exploring market dynamics and treatment expansion.
Challenges include managing expenses to sustain financial health and interpreting trial data for future research.
Opportunities lie in exploring additional indications, commercial planning, and reshaping patient care with transformative treatments.

MindMed reports strong Q2 earnings, advances Phase III programs

Mind Medicine (MNMD) showcased strong performance in Phase III programs, fundraising, and financials, positioning the company well for future growth and clinical advancements.
With a focus on operational efficiency, patient recruitment, and data integrity, MindMed is poised to address unmet needs in brain health disorders and drive market expansion.
Challenges lie in meeting upcoming milestones, global market analysis, and maintaining data integrity in Phase III trials, but opportunities abound in R&D expansion and market penetration strategies.
Overall, MindMed's strategic focus on Phase III trials, regulatory pathways, and market launch strategies sets a clear path for future success and growth in the brain health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Mind Medicine is a leading psychedelic pharmaceutical company and the first to be publicly listed. On Thursday, it became the first NEO-listed company to be included in an MSCI Index.

Stockwatch: MindMed Is Added To The MSCI Small Cap Canada Index

TORONTO--(BUSINESS WIRE)-- #MSCI--MSCI Inc. now recognizes NEO as an eligible market for inclusion in MSCI Indexes under the MSCI Global Investable Market Indexes Methodology.

NEO Exchange Announces Eligibility In MSCI Indexes

NEW YORK, May 27, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) ("MindMed" or the "Company") is pleased to announce that each of the resolutions put before the annual and special meeting of shareholders held today (the "Meeting") was passed by the requisite majority of shareholders. As described in the Company's management information circular dated April 19, 2021 (the "Circular"), Jamon Alexander Rahn, Miriam Halperin Wernli, Stephen Hurst, Perry Dellelce, Bruce Linton and Brigid Makes were re-elected as directors of the Company.

MindMed announces shareholder Meeting Results

Psychedelic drugs may eventually be a big market. However, investors in MNMD stock may be getting in a little too early.

Mind Medicine Stock Is Not a Trip To Take Just Yet

NEW YORK, May 26, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, announced today the publication of the first pharmacogenetic data on LSD to help personalize dosing. The study results from a pooled secondary analysis of four Phase 1 studies that each used a randomized, double-blind, placebo-controlled, crossover design and were conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland.

MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data on LSD to Help Guide Personalized Dosing

MindMed (NASDAQ: MNMD) and Israel-listed Nextage Therapeutics have entered into an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates. The agreement utilizes Nextage's Brain Targeting Liposome System (BTLS) delivery technology.

MindMed Collaborates with Nextage Therapeutics for Brain Targeting Liposome System

Allied Esports Entertainment Inc

Coty

Casper Sleep

Drive Shack

Ammo

Sirius XM Holdings Inc

While no one likes to see red ink on their portfolio, a key benefit is that you now have more choices regarding cheap stocks to buy. The post 7 Cheap Stocks to Buy Now Under $10 appeared first on InvestorPlace.

7 Cheap Stocks to Buy Now Under $10

NEW YORK, May 24, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading clinical stage psychedelic medicine company, and Nextage Therapeutics (TASE: NXTG), an Israeli innovative drug development company, announce the execution of a Memorandum of Understanding (the "MOU") regarding the launch of an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates, leveraging Nextage's proprietary Brain Targeting Liposome System (BTLS) delivery technology, for which it has an exclusive license.  MindMed and Nextage will initially collaborate to optimize the delivery of drug products based on noribogaine, and ultimately other ibogaine derivatives, and will share development costs and intellectual property arising from the collaboration.

MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System

(Kitco News) - The day MindMed listed on the NASDAQ in late April, the share price more than doubled in one day from $2.73 a share to $5.80.

Why MindMed stock doubled in one day - JR Rahn

It has a shot of finding success. Yet, said success remains many years away.

The Jury's Still Out on Psychedelics Play MindMed Stock

MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), announced Thursday that it had obtained authorization from the local Swiss ethics committee to conduct the first clinical trial on mescaline. What Happened The psychedelic medicine biotech company noted that the study will examine the effects of various “doses of mescaline and the role of the serotonin 5-HT2A receptor in mescaline-induced altered state of consciousness.

MindMed To Conduct The First Modern Research On Mescaline In Switzerland

BASEL, Switzerland, May 20, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading clinical stage psychedelic medicine company, announced today the approval by the local Swiss ethics committee of the first clinical trial evaluating the acute effects of different doses of mescaline and the role of the serotonin 5-HT2A receptor in mescaline-induced altered states of consciousness (MDR-Study). The study will be conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland, and is planned to start this month.

MindMed Announces the Approval of Mescaline Study

NEW YORK, May 18, 2021 /PRNewswire/ --  Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) ("MindMed" or the "Company"), a leading clinical stage psychedelic medicine company, today announced it has entered into a letter of intent to partner with The Chopra Foundation to educate and build public awareness around the use of psychedelic medicines to treat mental illness, remove outdated stigmas, and ultimately research mental wellbeing approaches that can be used in psychedelic related psychotherapy. The two organizations plan to design and conduct research together surrounding altered states of consciousness, psychedelic psychotherapy, and their overall impact on mental wellbeing.

The Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental Wellbeing

Now that it has joined the Nasdaq Exchange, MNMD stock will have its ups and downs but firm financials should instill shareholder confidence. The post Strong Cash Balance Should Provide a Foundation for MindMed Stock appeared first on InvestorPlace.

Strong Cash Balance Should Provide a Foundation for MindMed Stock

MindMed (MNMD) stock is getting a boost on Monday following news from the FDA that allows the company to continue development. The post MNMD Stock: The Big News That Has MindMed Investors Psyched Today appeared first on InvestorPlace.

MNMD Stock: The Big News That Has MindMed Investors Psyched Today

After receiving Type C Meeting Responses from the FDA, MindMed (NASDAQ: MNMD) has selected Generalized Anxiety Disorder as an initial indication for its Project Lucy, evaluating LSD. The company is on target to formally submit its Investigational New Drug (IND) application for Project Lucy in Q3 and expects to launch its Phase 2b trial after that in Q4 2021.

MindMed Stock Moves Higher After Finalizing Generalized Anxiety Disorder As Initial Indication For LSD Trial

MindMed Finalizes Clinical Development Approach for LSD Targeting Generalized Anxiety Disorder as Initial Indication NEW YORK, May 17, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading clinical stage psychedelic medicine company, announces receipt of Type C Meeting Responses from FDA leading to the finalization of the Company's clinical development approach for Project Lucy by selecting Generalized Anxiety Disorder as an initial indication. MindMed is on target to formally submit its Investigational New Drug (IND) application for Project Lucy in Q3 2021 and expects to launch its Phase 2b clinical trial shortly thereafter in Q4 2021.

MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial

Ideanomics Inc

Salarius Pharmaceuticals Inc

Robinhood penny stocks to watch for the next half of May The post Penny Stocks On Robinhood For You May 2021 Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks On Robinhood For You May 2021 Watch List

NEW YORK, May 14, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) ("MindMed" or the "Company") is pleased to announce that it has appointed Dr. Sarah Y. Vinson as a director of the Company and a member of its audit committee, effective immediately.

MindMed Announces Appointment of Dr. Sarah Y. Vinson as Additional Director

NEW YORK, May 14, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed'' or the "Company") (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, has announced its quarterly financial results for the quarter ended March 31, 2021. Q1 2021 Financial Highlights (in USD) Total assets as of March 31, 2021 were $201 million, including $160 million in cash Net Cash Used in Operating Activities (Total Cash Burn) of $10 million for the quarter ended March 31, 2021 Net and comprehensive loss of $14 million for the three months ended March 31, 2021 Q1 2021 Business Highlights MindMed closed its acquisition of HealthMode, a leading machine learning digital medicine company, adding Bradford Cross as Chief Technology Officer to lead Albert and Dr. Daniel R Karlin as Chief Medical Officer MindMed began the first-ever clinical trial combining MDMA and LSD in collaboration with UHB Liechti Lab MindMed closed an upsized financing of $92 million CAD ($73 million USD) MindMed closed a subsequent private placement of $19.5 million CAD ($15.4 million USD) MindMed expanded its Microdosing Division adding a groundbreaking study evaluating LSD Microdosing through next-gen digital clinical markers MindMed added Chief Development Officer, Robert Barrow, with FDA Phase 2 Psilocybin clinical trial experience MindMed signed partnership with Swiss psychedelic drug discovery startup MindShift Compounds AG, expanding its development pipeline and IP portfolio with next-gen psychedelic and empathogenic compounds MindMed's LSD neutralizer study began in collaboration with UHB Liechti Lab MindMed added Stanford University Pritzker Professor of Psychiatry and Behavioral Sciences, Dr. Robert Malenka as Chair of its Scientific Advisory Board MindMed announced Its Inclusion in FTSE Russell Indexes Breakdown of Operating Activities Net cash provided through financing activities - $90 million Net cash used in operating activities - $10 million Net cash used for the acquisition of HealthMode - $0.5 million (primarily a stock deal) Management Update & Earnings Call Management will provide updates on its clinical pipeline status and a review of its Q1 2021 financials.

MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline

Mind Medicine Inc (NASDAQ: MNMD) was started to address mental wellness, CEO and co-founder J.R. Rahn told Benzinga's Global Small Cap Conference Thursday.

EXCLUSIVE: MindMed CEO Talks Mission To 'Discover, Develop And Deploy' Psychedelics

NEW YORK, May 13, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic-inspired medicine company has appointed Peter Mack PhD as Vice President of Pharmaceutical Development. As MindMed progresses it's Discover and Develop efforts for multiple commercial clinical programs including LSD and an ibogaine derivative, 18-MC, Peter will lead MindMed's product development activities across its entire portfolio of investigational drugs.

MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development

Allakos Inc

Horizon Pharma

ImmunityBio

I-Mab

SAGE Therapeutics

SpringWorks Therapeutics Inc

As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first on InvestorPlace.

7 of the Best Pharma Stocks to Buy Now

COMPASS Pathways

Psychedelics could be a game-changer for millions struggling with mental health. Here are some of the top ways to trade psychedelic stocks.

3 Top Psychedelic Stocks to Own Now

NEW YORK, May 5, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed" or the "Company") (NASDAQ: MNMD) (NEO: MMED), (DE: MMQ), a leading psychedelic-inspired medicine company announces the launch of its Project Angie to advance the development of psychedelics, including LSD, to treat pain conditions. MindMed is currently exploring two primary clinical indications for the treatment of pain.

News for Mind Medicine MindMed Stock (MNMD)